The Cole Memo

In a statement provided to The Cole Memo, Illinois state officials addressed questions surrounding cannabis seed sales.

Questions on the topic cannabis seed sales are not new.

In February 2020, the Chicago Tribune reported that the Pritzker administration was working with state agencies, cultivators, and dispensaries to develop a process that would allow medical cannabis patients to purchase cannabis seeds.

In 2022, the Illinois Cannabis Regulation Oversight Office (CROO) told me that the seed-to-sale tracking system, BioTrack, would require changes to accommodate the sale of “dynamic products, like seeds.”

After Illinois transitioned from BioTrack to Metrc, I wanted to know whether that technical limitation still existed. According to the agencies, the new system is capable of tracking and tracing cannabis seeds through the supply chain to retail sale.

“The new system is capable of tracking and tracing cannabis seeds through the supply chain to retail sale. IDFPR and IDOA are currently reviewing SB3222’s statutory updates regarding seeds.”

July 13, 2026

I followed up asking the agencies to clarify which statutory updates regarding seeds they were referring to. I have not identified any changes in SB3222 related to the sale of cannabis seeds through dispensaries, so, I asked the state to identify the specific statutory provisions that they were referencing. An IDFPR spokesperson responded:

“There are numerous policy and program areas in the law that require implementation, and the state is developing a plan to do so. We are reviewing all the updated language, including Section 15-70(p)(16), and the other CRTA sections that affect seeds, to ensure implementation is consistent with the law.”

June 14, 2026

Section 15-70(p)(16)

In the above follow-up response, the agencies specifically referenced Section 15-70(p)(16) of the Cannabis Regulation and Tax Act. That subsection provides:

“(p) A dispensing organization shall not:

…(16) Sell seed clones or any other live plant material, except to a qualifying medical patient, designated caregiver, provisional patient, or Opioid Alternative Patient Program participant.”

The agencies indicated that they are also reviewing other provisions of the CRTA that affect cannabis seeds as they implement the law.

Why this question matters now

For several years, many Illinois home growers have been able to obtain cannabis seeds through garden centers, hydroponic retailers, and online vendors marketing seeds through the hemp market.

Because those products have generally remained legal and readily available, the question of whether Illinois dispensaries sold cannabis seeds has not been particularly urgent for many medical cannabis patients.

That could soon change.

Beginning later this year, Senate Bill 3222 will subject cannabis products, including products currently marketed through the hemp market, to the Cannabis Control Act when sold outside Illinois’ regulated dispensary system. As a result, the Illinois cannabis industry could become an increasingly important source for patients seeking to lawfully obtain cannabis seeds for home cultivation.

State officials have now indicated that Illinois’ seed-to-sale system is capable of tracking and tracing cannabis seeds through the regulated supply chain to retail sale. The questions that remain largely center on implementation.

As the agencies work through that process, I took the opportunity to ask other questions that could affect registered qualifying medical cannabis patients that want to grow at home. I asked how cannabis seed purchases would affect a patient’s purchasing allotment, if at all, and how many seeds a patient may purchase and how often.

An IDFPR spokesperson told me those questions have been forwarded to the agencies’ subject matter experts and that they will provide additional information when it becomes available.

I’ll publish a follow-up article as additional information becomes available.

Comment below with your thoughts and consider supporting my work!

You can support The Cole Memo with a one-time, monthly, or yearly contribution.

#300 – Illinois Has More Cannabis Brands Than Ever. Fewer Companies Own Them. – The Cole Memo

Damian Fagon, policy director at the Parabola Center for Law and Policy, joins the show to discuss a new analysis of Illinois' cannabis market and the structural advantages held by large multi-state operators and incumbent medical cannabis companies. We discuss market concentration, cultivation capacity, vertical integration, management agreements, consumer choice, and why hundreds of cannabis brands may create an illusion of competition. Damian also discusses continued cannabis arrests after legalization, the role of corporate influence in cannabis policy, New York's approach to legalization, and why he believes states must put consumers, small businesses, and civil liberties ahead of commercialization. Watch video version and read full show notes here: https://thecolememo.com/2026/07/08/e300/

1. #300 – Illinois Has More Cannabis Brands Than Ever. Fewer Companies Own Them. 01:27:46
2. #299 – Oregon's Legal Psilocybin Experiment Faces a Major Test 45:11
3. #298 – Illinois Signs Major Cannabis Overhaul, Plus Q&A With Brad Spirrison 01:19:50
4. #297 – Illinois Homegrow: Can Medical Patients Actually Buy Cannabis Seeds? 56:25
5. #296 – Federal Cannabis Rescheduling Hearings Begin: Key Takeaways from Days 1 & 2 32:59